Key Points
- Use the highest‑yield diagnostic test early; do not let testing delay time‑critical therapy.
- Set objective targets and reassess frequently.
- Plan definitive source control or disease‑specific therapy when indicated; document follow‑up and patient education.
Algorithm
- Assess TLS risk; start hydration ± allopurinol before chemotherapy.
- If TLS develops or high-risk labs → rasburicase; aggressive electrolyte management.
- Consider RRT for refractory hyperkalemia, acidosis, or volume overload; continue intensive monitoring.
Clinical Synopsis & Reasoning
Rapid tumor cell breakdown after cytotoxic therapy (or spontaneously) causing hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. Risk‑stratify, start aggressive hydration, give allopurinol for prevention or rasburicase for treatment, and monitor electrolytes/renal function closely; initiate dialysis when refractory.
Treatment Strategy & Disposition
Stabilize ABCs. Initiate guideline‑concordant first‑line therapy with precise dosing and continuous monitoring. Escalate to advanced/procedural interventions based on explicit failure criteria. Define ICU, step‑down, and ward disposition triggers; involve specialty teams early.
Epidemiology / Risk Factors
- Risk varies by comorbidity and precipitants; see citations for condition‑specific data.
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|
| Cairo‑Bishop criteria labs q4–6 h | Diagnosis/severity | Electrolyte derangements and creatinine rise | Trend closely |
| ECG and telemetry | Safety | Arrhythmia risk with K+/Ca2+ changes | — |
| Urine output monitoring and ultrasound (selected) | Complications | Obstruction/AKI | Guide RRT |
High-Risk & Disposition Triggers
| Trigger | Why it matters | Action |
|---|
| High-risk regimens or bulky, chemosensitive tumors | Impending TLS | Prophylaxis with hydration + allopurinol/rasburicase; ICU if severe |
| Uric acid >8 mg/dL, K+ >6, Phos >6 with rising Cr | Renal failure/arrhythmia risk | Rasburicase; dialysis if refractory |
| Oliguria/volume overload | Worsening clearance | Diuretics; consider CRRT |
| Severe hypocalcemia with tetany/arrhythmia | Life-threatening | Treat cautiously; correct phosphate first |
| G6PD deficiency (rasburicase) | Hemolysis risk | Check status; avoid if deficient |
Pharmacology
| Medication/Intervention | Mechanism | Onset | Role in Therapy | Limitations |
|---|
| Aggressive IV hydration 2–3 L/m²/day | Prevention/treatment | Hours | Enhance excretion | Avoid K+/Ca2+ fluids |
| Allopurinol 300 mg/day (or weight‑based pediatrics) for prophylaxis | XO inhibitor | Days | Prevents uric acid formation | Start before chemo |
| Rasburicase 0.1–0.2 mg/kg IV (treatment) | Uricolytic enzyme | Hours | Rapidly lowers uric acid | Screen for G6PD deficiency |
| Manage K+/Phos/Ca with standard protocols | Electrolyte control | Hours | Prevent arrhythmia/AKI | Dialysis if refractory |
Prognosis / Complications
- Outcome depends on timeliness of diagnosis and definitive therapy; monitor for complications.
Patient Education / Counseling
- Provide red‑flag education, adherence guidance, and explicit return precautions; arrange timely specialty follow‑up.
References
- ASCO/ASH TLS guidance — Link